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Hypoxia is closely associated with the radioresistance of tumours; therefore, targeting hypoxic areas is very important for cancer therapy.
The aim of this study is to establish such a targeting strategy by applying a bacterial cytosine deaminase (BCD)/5-fluorocytosine (5-FC)
gene therapy system and to examine whether the strategy enhances the efficacy of radiotherapy in a tumour xenograft. The hypoxia-
responsive promoter 5HREp, in which five copies of the hypoxia-response element (HRE) enhance transcription from a cytomegalovirus
minimal promoter, was employed to induce the expression of BCD under hypoxic conditions. The adenoviral vector Ad/5HREp-BCD,
encoding the gene 5HREp-BCD, robustly induced BCD expression under hypoxic conditions and this led to significant cytotoxicity in
combination with 5-FC in vitro. Intratumoral Ad/5HREp-BCD administration resulted in the expression of BCD at the border between
normoxic and necrotic regions. The BCD/5-FC gene therapy enhanced the therapeutic effects of both single (12.5Gy) and fractionated
(3Gy 5 days) radiotherapy with few side effects and significantly increased tumour growth doubling time by up to 2.4-fold (Po0.01)
and 2.5-fold (Po0.05), respectively. All of these results suggest that the present BCD/5-FC gene therapy has the ability to specifically
target hypoxic tumour cells and significantly improves the control of tumour growth after radiotherapy.
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The exponential proliferation of cancer cells and the resultant
distance that develops between nutritive blood vessels and some
tumour cells result in an imbalance in the supply and consumption
of oxygen in solid tumours. Such disequilibrium is a major
causative factor of tumour hypoxia, a characteristic microenviron-
ment in locally advanced solid tumours (Thomlinson and Gray,
1955; Vaupel et al, 1989). The hypoxia is closely associated with
malignant phenotypes (Graeber et al, 1996), metastasis (Rofstad,
2000), invasion (Pennacchietti et al, 2003), and angiogenesis
(Harris, 2002). The hypoxic fraction correlates to the resistance to
chemotherapy (Teicher, 1994) and radiotherapy (Thomlinson and
Gray, 1955; Brown and Wilson, 2004). Therefore, not only has
tumour hypoxia been considered an adverse prognostic indicator,
but also, a hypoxia-targeting strategy is becoming increasingly
important to overcome these problems (Teicher, 1994; Harris,
2002; Brown and Wilson, 2004).
Under hypoxic conditions, hypoxia-inducible factor-1 (HIF-1)
plays a pivotal role in inducing the expression of various genes
(Semenza, 2001). Hypoxia-inducible factor-1 is a heterodimeric
transcription factor composed of an a-subunit (HIF-1a) and a
b-subunit (HIF-1b) (Wang et al, 1995). The expression of HIF-1a is
regulated in an oxygen-dependent manner mainly at the post-
translational level and is responsible for the regulation of HIF-1’s
activity (Kallio et al, 1997). Proline residues in the oxygen-
dependent degradation domain of HIF-1a protein are hydroxylated
under normoxic conditions (Jaakkola et al, 2001). The modified
HIF-1a protein is ubiquitinated by E3 ubiquitin–protein ligases
containing the von Hippel–Lindau tumour suppressor protein
(pVHL) and rapidly degraded by the 26S proteasome (Jaakkola
et al, 2001). On the other hand, the rate at which proline was
hydroxylated decreased under hypoxic conditions, resulting in a
reduced rate of ubiquitination and subsequent degradation
(Jaakkola et al, 2001). The stabilised HIF-1a interacts with the
constitutively expressed HIF-1b protein and induces the gene
expression of erythropoietin (Wang and Semenza, 1993), VEGF
(Forsythe et al, 1996), and others (Semenza, 2001). The induction
is triggered by the interaction of HIF-1 with its cognate DNA
recognition site, the hypoxia-response element (HRE) (Norris and
Millhorn, 1995; Forsythe et al, 1996). An increased level of HIF-1a
in the tumour and the resultant upregulation of HIF-1 activity as
well as tumour hypoxia have been associated with tumour
malignancy, aggressive tumour growth, tumour radioresistance
and a poor prognosis (Powis and Kirkpatrick, 2004).
Extensive efforts have focused on the development of biological
approaches to deal with tumour hypoxia (Semenza, 2003; Brown
and Wilson, 2004). One of the most striking advances is the
development of artificial hypoxia-responsive promoters (Greco
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set al, 2000), in which the HRE(s) has been utilised as a
transcriptional enhancer. Many groups have reported that a
tandem repeat of HREs enhances gene expression under hypoxic
conditions (Greco et al, 2000). Above all, the 5HRE promoter
(5HREp), in which five copies of the HRE enhance transcription
from a cytomegalovirus (CMV) minimal promoter, enhances gene
expression more than 500-fold under hypoxic conditions in vitro
(Shibata et al, 1998, 2000; Greco et al, 2000). Optical imaging of
tumour hypoxia by using the 5HREp-luciferase gene and the
5HREp-green fluorescent protein (GFP) gene has proved the
potential of the promoter in vivo as well as in vitro (Vordermark
et al, 2001; Harada et al, 2005; Liu et al, 2005). Hypoxia-specific
targeting was also accomplished in vivo, when cytotoxic genes or
therapeutic genes, such as for apoptotic factors or prodrug-
activating enzymes, were inserted downstream of the hypoxia-
responsive promoters (Greco et al, 2000; Koshikawa et al, 2000;
Patterson et al, 2002; Shibata et al, 2002; Binley et al, 2003; Ogura
et al, 2005). However, all of these in vivo experiments were
conducted using stable transfectants with each hypoxia-responsive
gene. In other words, no one has examined whether 5HREp would
function in a trans-acting gene therapy strategy.
In the present study, we utilised 5HREp (Shibata et al, 2000) and
a prodrug-activating gene, bacterial cytosine deaminase (BCD)
(Mullen et al, 1992; Miller et al, 2002), and successfully established
an adenovirus-mediated gene therapy strategy for tumour hypoxia.
We used this strategy to determine whether the specific targeting
of tumour hypoxia by gene therapy improves the efficacy of
radiotherapy in a tumour xenograft.
MATERIALS AND METHODS
Cell culture
The human cervical epithelial adenocarcinoma cell line HeLa and
the human pancreatic carcinoma cell line MIA PaCa-2 were
maintained in Dulbecco’s modified Eagle’s medium with 10% fetal
bovine serum. The human pancreatic carcinoma cell line CFPAC-1
was maintained in Iscove’s modified Dulbecco’s medium (IMDM)
with 10% fetal bovine serum. The human colon carcinoma cell
lines WiDr and HT29 were maintained in RPMI-1640 medium with
10% fetal bovine serum. All cell lines were purchased from
American Type Culture Collection. For normoxic incubation, the
cells were incubated in a well-humidified incubator with 5% CO2
and 95% air at 371C.
Plasmid DNA
To construct the plasmid pEF/BCD, which constitutively expresses
a BCD protein fused to a myc epitope tag under the control of the
EF-1a promoter, a DNA fragment for the Escherichia coli codA
gene, which encodes the enzyme cytosine deaminase, was
amplified by PCR and inserted between NcoI and NotI recognition
sites of the vector pEF/myc/cyto (Invitrogen, Carlsbad, CA, USA).
To construct the plasmid p5HRE/BCD, which induces the
expression of the BCD-myc fusion protein under hypoxic
conditions, a DNA fragment for 5HREp was obtained by digestion
with KpnI and NcoI from the vector, 5HRE/hCMVmp (Shibata
et al, 2000), inserted between KpnI and NcoI recognition sites of
pEF/BCD, and substituted for the constitutive EF-1a promoter.
Stable transfectants
To establish stable transfectants, HeLa/EFp-BCD and HeLa/
5HREp-BCD, HeLa cells (1 10
5) were transfected with pEF/BCD
and p5HRE/BCD, respectively, by a modified calcium–phosphate
method (Chen and Okayama, 1987, 1988). Twenty-four hours after
the transfection, the culture medium was refreshed with selection
medium containing 5mgml
 1 of blasticidine for HeLa/EFp-BCD
cells or 400mgml
 1 of G418 for HeLa/5HREp-BCD cells. Each
antibiotic-resistant cell culture was directly used for both the
Western blot analysis and the in vitro cell proliferation assay.
Construction, amplification, and infection of the
adenovirus
To construct cosmid vectors, pAxcw/EFp-BCD and pAxcw/5HREp-
BCD, DNA fragments for EFp-BCD and 5HREp-BCD were prepared
from pEF/BCD and p5HRE/BCD, respectively, by digestion with
KpnI and BamHI, blunted and inserted into the SwaI recognition
site of the cosmid vector pAxcw (TaKaRa, Tokyo, Japan). The
recombinant adenoviruses, Ad/EFp-BCD and Ad/5HREp-BCD,
were generated by COS–TPC methods (Miyake et al, 1996) using
an adenovirus expression kit according to the manufacturer’s
instructions (TaKaRa). For large-scale preparations, the adeno-
viruses were amplified in a transformed human embryonic kidney
cell line, 293, and purified by two steps of caesium chloride density
centrifugation. Viral titers were measured in a limiting-dilution
bioassay using 293 cells. Cells (1 10
5cells per dish) were seeded
onto a 60mm dish and treated with Ad/EFp-BCD or Ad/5HREp-
BCD for 1h. Then, the adenovirus-containing medium was
replaced with one without the virus.
Western blot analysis
The stable transfectants and the virus-infected cells were seeded in
60mm glass dishes (2 10
5cells per dish), put into pre-warmed
aluminium chambers, and flushed with hypoxic gas (95% N2,5 %
CO2) for 30min. Then, tightly sealed chambers were incubated at
371C for 16h for the hypoxic treatment. The cells were harvested in
RIPA lysis buffer (10% SDS, 2 M Tris-HCl, pH 7.5, and 1% Triton X)
supplemented with a protease inhibitor, Mini complete (Roche,
Basel, Switzerland). The lysates were sheared using a syringe with a
23-gauge needle, and the protein concentration was determined
using the DC Protein assay kit (Bio-Rad). Twenty micrograms of
total protein was electrophoresed on a 12% SDS polyacrylamide gel,
transferred onto PVDF membrane (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ, USA) and blocked with 5% non-fat milk in
Tris-buffered saline. The BCD protein fused to the myc epitope tag
was detected with monoclonal anti myc-tag antibody (Cell
Signaling Technology Inc., Danvers, MA, USA) and anti mouse
IgG horseradish peroxidase-linked whole antibody (GE Healthcare
Bio-Sciences Corp.) using an ECL-PLUS system (GE Healthcare
Bio-Sciences Corp.) according to the manufacturer’s instructions.
In vitro cell proliferation assay
The stable transfectants and the virus-infected cells were seeded in
triplicate into 96-well plates (1 10
3cells per well) and incubated
with various concentrations of 5-fluorocytosine (5-FC) (Sigma
Chemical Co., St Louis, MO, USA) for 24h under normoxic or
hypoxic conditions. For the hypoxic treatment (o0.02% of
oxygen), the cells were treated in a hypoxic chamber, BAC-
TRON-II (Sheldon Manufacturing Inc., Cornelius, OR, USA). The
cells were additionally incubated under normoxic conditions for
24h. The culture medium was then changed to one without 5-FC,
and the cells were cultured for 48h under the normoxic conditions.
Cell growth inhibition was quantified by colorimetric assay using a
CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit
(Promega, Madison, WI, USA) according to the manufacturer’s
instructions.
Tumour-bearing mice
A suspension of HeLa cells (2 10
6cells/100ml of PBS) was
subcutaneously inoculated into the right hind leg of a 6-week-old
nu/nu BALB/c mice (Charles River, Tokyo, Japan).
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sImmunohistochemical analysis
The adenovirus Ad/EFp-BCD or Ad/5HREp-BCD was intra-
tumorally injected into the HeLa tumour xenografts, when the
xenografts developed to approximately 150–200mm
3. Four days
later, pimonidazole hydrochloride (Natural Pharmacia Interna-
tional Inc., Belmont, MA, USA) was intraperitoneally (i.p.) injected
into the tumour-bearing mice (60mgkg
 1). Ninety minutes later,
the tumours were surgically excised, immediately fixed in 10%
formalin neutral buffer solution (pH¼7.4; Wako Pure Chemical
Industries Inc., Osaka, Japan), and embedded in paraffin. To detect
pimonidazole and BCD-myc, paraffin-embedded sections were
treated with anti-pimonidazole (Natural Pharmacia International
Inc.) and anti-c-myc antibody (Santa Cruz, CA, USA), respectively,
and stained using an indirect immunoperoxidase detection
method (DakoCytomation, Carpinteria, CA, USA), according to
the manufacturer’s instructions. Counterstaining with haematox-
ylin was also carried out. Paraffin-embedded serial sections were
also stained with haematoxylin–eosin (HE).
Radiation conditions
The tumour-bearing mice were irradiated at 1.468Gymin
 1 with
an X-ray irradiation machine (SHIMADZU, Kyoto, Japan). All the
tumour-bearing mice were restrained and shielded with a specially
designed lead apparatus that allowed local irradiation to the
tumour on the right hind leg.
Growth delay assays
When the tumour xenografts developed to approximately 150–
200mm
3, the tumour-bearing mice were randomly divided into
five treatment groups: (1) a sham-treated group, (2) an Ad & 5-FC
group, (3) an ionising radiation (IR) group, (4) an IR & 5-FC group
and (5) an Ad & 5-FC & IR group. In the single irradiation
experiment, 2 10
9PFU of adenovirus was intratumorally injected
into the mice of the Ad & 5-FC and Ad & 5-FC & IR groups on day
0. 5-FC (500mgkg
 1) was i.p. injected into the mice of the Ad & 5-
FC, IR & 5-FC, and Ad & 5-FC & IR groups on both day 1 and day
2. Irradiation (12.5Gy) was applied to the mice of the IR, IR & 5-
FC, and Ad & 5-FC & IR groups 12h after the injection of 5-FC on
day 1. In the fractionated irradiation experiment, the adenovirus
was intratumorally injected into the mice of the Ad & 5-FC and Ad
& 5-FC & IR groups on day 0. 5-Fluorocytosine was administered
daily from day 1 to day 5 to the mice of the Ad & 5-FC, IR & 5-FC,
and Ad & 5-FC & IR groups. Irradiation was applied 12h after the
injection of 5-FC daily from day 1 to day 5 to the mice of the IR, IR
& 5-FC, and Ad & 5-FC & IR groups (3Gy 5 days). For the
negative control, PBS was injected instead of the adenovirus and
the 5-FC. The tumour size was measured with calipers, and the
tumour volume was calculated as 0.5LW
2.
Statistical analysis
The statistical significance of differences was determined using the
Student’s t-test (Po0.05).
RESULTS
Establishment of a hypoxia-dependent prodrug-activating
system
To establish a hypoxia-targeting gene therapy strategy, we first
constructed a plasmid, p5HRE/BCD, encoding the 5HREp-BCD
gene (Figure 1A). Shibata et al (2000) employed 5HREp to induce
the therapeutic gene expression specifically under hypoxic
conditions. The BCD gene was used as the prodrug-activating
gene, because the intratumoral production of 5-fluorouracil by the
BCD/5-FC system is effective for cancer therapy (Mullen et al,
1992; Miller et al, 2002). HeLa cells were stably transfected with
p5HRE/BCD and the hypoxia dependency of the BCD expression
was examined by Western blot analysis (Figure 1B). The stable
transfectant, HeLa/5HREp-BCD, expressed the BCD protein only
under hypoxic conditions, while the HeLa/EFp-BCD cells, which
had been expected to express constitutively the protein, indeed
expressed BCD regardless of the conditions. We next examined
whether the hypoxia-dependent BCD expression led to the
hypoxia-specific cytotoxicity. The HeLa/5HREp-BCD cells were
treated with various concentrations of 5-FC under normoxic or
hypoxic conditions, and the growth inhibitory effects were
assessed by MTS assay. Significant growth inhibition was observed
only under hypoxic conditions (Po0.05 with 0.1mgml
 1 of 5-FC,
Po0.01 with 1 and 10mgml
 1 of 5FC). There was no significant
inhibition observed under normoxic conditions (Figure 1C). On
the other hand, HeLa/EFp-BCD cells showed hypoxia-independent
sensitivity to the 5-FC treatment (Figure 1D). Thus, we confirmed
that the 5HREp-dependent BCD/5-FC strategy led to the hypoxia-
specific cytotoxicity.
Ad/5HREp-BCD-mediated cytotoxicity under hypoxic
conditions
We decided to use an adenovirus to transduce the 5HREp-BCD
gene into tumour cells in vivo, because the adenovirus is one of the
most effective vectors with which to accomplish trans-gene
expression. We constructed a cosmid vector, pAxcw/5HREp-BCD
(Figure 2A), and obtained the adenovirus, Ad/5HREp-BCD, by the
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Figure 1 Hypoxia-responsive BCD expression and 5-FC sensitivity. (A)
Schematic diagrams of the EFp-BCD gene constitutively expressing the BCD
(top) and the 5HREp-BCD gene hypoxia-dependently expressing the BCD
(bottom). The BCD coding gene was fused to the myc epitope in frame.
(B) Western blot analysis of BCD-myc expression in HeLa/EFp-BCD cells
or HeLa/5HREp-BCD cells under normoxic (N) or hypoxic (H) conditions.
(C and D) Cell proliferation assay of HeLa/5HREp-BCD cells (C) and
HeLa/EFp-BCD cells (D). The cells were treated with various concentra-
tions of 5-FC under normoxic (open) or hypoxic (solid) conditions. Cell
viability was calculated as the ratio of the absorbance value in each of the
conditions against that in medium with 0.001mgml
 1 of 5-FC under
normoxic conditions. Results are the mean7s.d. (n¼3). *Po0.05.
**Po0.01.
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sCOS–TPC methods (Miyake et al, 1996). To examine whether
Ad/5HREp-BCD showed hypoxia-dependent BCD expression, we
performed a Western blot analysis (Figure 2B). HeLa cells were
infected with Ad/5HREp-BCD at a MOI of 10–100 and cultured
under normoxic or hypoxic conditions. The BCD protein was
expressed only under hypoxic conditions. The amount of BCD
protein expressed and the ratio of the expression under hypoxia to
that under normoxia increased with the increase in the MOI. On
the other hand, HeLa cells infected with Ad/EFp-BCD constitu-
tively expressed BCD protein regardless of oxygen conditions
(Figure 2B).
We next evaluated the hypoxia dependency and the therapeutic
efficacy of the Ad/5HREp-BCD-mediated strategy in vitro. The
virus-infected HeLa cells were exposed to various concentrations
of 5-FC under normoxic or hypoxic conditions, and the growth
inhibitory effect was examined by MTS assay (Figure 3A). The cell
proliferation was significantly inhibited under hypoxic conditions
compared to normoxic conditions when the cells were treated with
Ad/5HREp-BCD (MOI¼100) and the higher concentration of
5-FC. Likewise, MIA PaCa-2 and WiDr cells showed hypoxia-
dependent sensitivity to the adenovirus-mediated BCD/5-FC
treatment (Figure 3B and C). On the other hand, proliferation
was inhibited under both normoxic and hypoxic conditions, when
the cells were infected with Ad/EFp-BCD (MOI¼100). All of the in
vitro experiments clearly indicate that our system functioned as we
desired.
Hypoxia-specific BCD expression after intratumoral
Ad/5HREp-BCD injection
We examined whether Ad/5HREp-BCD induces the expression of
BCD in hypoxic regions of the tumour xenograft. The virus
(1 10
9pfu) was intratumorally injected into HeLa tumour
xenografts, and the regions expressing BCD were compared to
those stained with a marker of hypoxia, pimonidazole (Durand
and Raleigh, 1998). The immunohistochemical analysis showed
that the hypoxic cells stained with pimonidazole were located
about 100mm from a tumour blood vessel, and a robust expression
of BCD was also observed there (Figure 4A–C). On the other hand,
remarkable BCD expression was observed in well-oxygenated
viable regions after intratumoral injection of Ad/EFp-BCD (Figure
4D and E). These results suggest that the trans-gene expression of
BCD in hypoxic tumour cells can be achieved by the intratumoral
administration of the adenovirus Ad/5HREp-BCD.
Improvement of radiotherapy by
Ad/5HREp-BCD-mediated gene therapy
The in vitro cell proliferation assay (Figure 3) and the immuno-
histochemical analysis (Figure 4) led us to expect a hypoxia-
specific therapeutic effect of the Ad/5HREp-BCD, and 5-FC gene
therapy. Actually, we confirmed an advantage of 5HREp concern-
ing side effects on normal tissues. The Ad/5HREp-BCD/5-FC gene
therapy caused no obvious side effects, while the Ad/EFp-BCD/5-
FC gene therapy, despite the local administration, caused
significant weight loss (Figure 5A) and severe diarrhea (data not
shown). This result indicates that our system functioned, as we
desired.
We next examined whether the combination of the Ad/5HREp-
BCD/5-FC gene therapy with radiotherapy produced a synergistic
antitumour effect. We treated HeLa tumour xenografts with the
gene therapy (Ad & 5-FC) and/or radiotherapy (IR) and carried
out growth delay assays (Figure 5B). We intentionally chose a
relatively low dose of Ad & 5-FC, which had minimal effects on the
tumour growth rate. Therefore, tumour growth after the gene
therapy alone (Ad & 5-FC group) was not significantly suppressed
compared to that after sham-treatment (sham-treated group). On
the other hand, combined with IR (Ad & 5-FC & IR group), the
gene therapy strikingly suppressed tumour growth as compared to
radiotherapy alone (IR group). The period taken for tumour
growth to increase two-fold from the initial volume (tumour
growth doubling time, TGDT) more clearly shows the therapeutic
effect of the treatment (Table 1). The TGDT after gene therapy
alone (Ad & 5-FC group) was 13.275.6 days, which is not
significantly longer than that after sham-treatment (8.273.1 days;
P¼0.144). On the other hand, the combination of gene therapy
with radiotherapy (Ad & 5-FC & IR) prolonged the TGDT to
47.2716.8 days, which was about 2.4-fold longer than that after
radiotherapy alone (IR group; 19.474.8 days; Po0.01). Thus, we
confirmed that the adenovirus-mediated and hypoxia-targeting
gene therapy significantly enhances the effect of radiotherapy.
Similar results were obtained in the experiment using the
fractionated irradiation (3Gy 5 fractions: Figure 5C). The TGDT
after gene therapy alone (Ad & 5-FC group) was 13.074.4 days,
which is not significantly longer than that after sham treatment
(9.875.8 days; P¼0.148). On the other hand, the TGDT after the
fractionated radiotherapy (IR) was 17.073.7 days, which was
significantly delayed by the combination with the gene therapy (Ad
& 5-FC & IR group) to 43.3723.8 days (Table 1; Po0.05). These
results further strengthen the conclusion that hypoxia targeting by
gene therapy improves the efficacy of radiotherapy.
DISCUSSION
In the present study, we established a hypoxia-targeting strategy by
applying a BCD/5-FC gene therapy system and examined whether
the strategy enhances the efficacy of radiotherapy in a tumour
xenograft.
Because tumour hypoxia has been recognised as a tumour-
specific microenvironment, recent research has tried to exploit it
as a crucial target for cancer therapy (Harris, 2002; Semenza, 2003;
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Figure 2 Adenovirus-mediated BCD expression under hypoxic condi-
tions. (A) Schematic diagrams of the cosmid vectors, pAxcw/EFp-BCD
(top) and pAxcw/5HREp-BCD (bottom), encoding EFp-BCD and 5HREp-
BCD, respectively. Ori¼replication origin; Amp
R¼ampicillin-resistance
gene; COS¼cos (phage l sequences) region (B) Western blot analysis of
BCD-myc expression by using anti myc-tag antibody. HeLa cells were
infected with Ad/EFp-BCD or Ad/5HREp-BCD at the indicated MOI, and
exposed to normoxic (N) or hypoxic (H) conditions.
Hypoxia-specific gene therapy enhances radiotherapy
J Liu et al
1874
British Journal of Cancer (2007) 96(12), 1871–1878 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s0
0.2
0.4
0.6
0.8
1
1.2
0
0.2
0.4
0.6
0.8
1
1.2
0
0.2
0.4
0.6
0.8
1
1.2
0.1 1 10 0.1 1 10 0.1 1 10
Normoxic
Hypoxic
Normoxic
Hypoxic
Normoxic
Hypoxic
5-FC (mg/ml)
5-FC (mg/ml)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
0
0.2
0.4
0.6
0.8
1
1.2
0.1 1 10
C
e
l
l
 
v
i
a
b
i
l
i
t
y
0
0.2
0.4
0.6
0.8
1
1.2
0.1 1 10
C
e
l
l
 
v
i
a
b
i
l
i
t
y
0
0.2
0.4
0.6
0.8
1
1.2
0.1 1 10
5-FC (mg/ml)
0
0.2
0.4
0.6
0.8
1
1.2
0.1 1 10
0
0.2
0.4
0.6
0.8
1
1.2
0
0.2
0.4
0.6
0.8
1
1.2
0.1 1 10
0.1 1 10
Mock Ad/5HREp-BCD Ad/EFp-BCD
HeLa
* **
**
* *
Mock Ad/5HREp-BCD Ad/EFp-BCD
MIA PaCa-2
* * *
Mock Ad/5HREp-BCD Ad/EFp-BCD
WiDr
* *
** *
Normoxic
Hypoxic
Normoxic
Hypoxic
Normoxic
Hypoxic
Normoxic
Hypoxic
Normoxic
Hypoxic
Normoxic
Hypoxic
A
B
C
Figure 3 Ad/5HREp-BCD-mediated cytotoxicity. (A) HeLa, (B) MIA PaCa-2, and (C) WiDr cells were infected with the adenovirus, Ad/EFp-BCD or Ad/
5HREp-BCD, and treated with various concentrations of 5-FC under normoxic (open) or hypoxic (solid) conditions. Cell viability was calculated as the ratio
of the absorbance value under each of the conditions against that in medium with 0.1mgml
 1 of 5-FC under normoxic conditions. The same experiment
was conducted with mock infection. Results are the mean7s.d. (n¼3). *Po0.05. **Po0.01.
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Figure 4 Immunohistochemical analysis of BCD expression in virus-injected tumour xenografts. The tumour xenograft of HeLa cells was intratumorally
injected with Ad/5HREp-BCD (A–C) or Ad/EFp-BCD (D and E). Serial sections of the xenograft were subjected to HE staining (A and D), and to
immunohistochemical analysis with anti-c-myc antibody for the detection of BCD-myc (B and E), and with anti-pimonidazole antibody (C). Bar¼100mm.
N¼necrotic tumour tissue; V¼well-oxygenated viable tumour tissue; arrow¼blood vessel.
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sBrown and Wilson, 2004). In this regard, the hypoxia-specific gene
therapy strategy has been focused on, and artificial hypoxia-
responsive promoters have been developed using various kinds of
HREs, such as murine PGK-1 HRE, human erythropoietin HRE,
and human VEGF HRE (Greco et al, 2000). Above all, 5HREp
showed the best hypoxia-responsiveness and exhibited a more
than 500-fold increase in luciferase activity in response to hypoxic
stimuli (Shibata et al, 2000). The absolute level of luciferase
activity from 5HREp under the hypoxic conditions reached the
same level as that from the CMV-driven promoter under normoxic
conditions (Shibata et al, 2000). Consistent with these previous
reports, the expression of BCD was robustly induced under
hypoxic conditions in our plasmid based and adenovirus-based
Western blot analysis. This induction actually led to significant
hypoxia-dependent cytotoxicity in our cell proliferation assay.
The sensitivity of each cell line to the Ad/5HREp-BCD/5-FC
treatment varied in the present cell proliferation assay (Figure 3;
compare the viability of each cell line at MOI¼100). Among the
cell lines tested, HeLa cells exhibited the highest hypoxia
dependency concerning sensitivity to the treatment. On the other
hand, a human colon carcinoma cell line, HT29, and a human
pancreatic carcinoma cell line, CFPAC-1, showed little therapeutic
efficacy (Supplementary Figure S1A and B). We hypothesised that
this variability might be caused by the difference in the efficiency
of adenoviral infection in each cell line, because it was reported
that cells showed different infection efficiencies and CFPAC-1 cells
had the lowest transduction efficiency among cells tested (Bouvet
et al, 1998). We performed a chemiluminescent b-gal assay to
analyse the efficiency of the adenoviral infection and confirmed
that HeLa cells showed the highest, and HT29 and CFPAC-1 cells, a
much lower, infection efficiency (Supplementary Table S1).
Moreover, when we transfected HT29 and CFPAC-1 cells with
p5HRE/DsRed2 plasmid (not an adenovirus), we confirmed the
presence of hypoxia-dependent red fluorescence, indicating that
the 5HREp works in these cells (Supplementary Figure S2).
Therefore, we concluded that the low infection efficacy of the
adenovirus was responsible for the weak therapeutic efficacy in
HT29 and CFPAC-1 cells. These results indicate that, although
hypoxia is a common feature of solid tumours, our hypoxia-
targeting system cannot target all tumour hypoxia without an
excellent vector.
To measure the damage to normal tissue after hypoxia-targeting
treatment, Binley et al (2003) applied a hypoxia-responsive
thymidine kinase/ganciclovir (TK/GCV) strategy and evaluated
the activity of lactate dehydrogenase (LDH) as an indicator of liver
dysfunction. Hypoxia-dependent TK expression and GCV treat-
ment caused no irregularity in LDH levels. On the other hand,
constitutive TK expression from a CMV promoter and GCV
treatment significantly elevated LDH levels in mice. These results
suggest that a hypoxia-responsive promoter would facilitate target-
specificity and so reduce the side effects on well-oxygenated
normal tissues. Consistent with these reports, we did not observe
any obvious side effects after the Ad/5HREp-BCD/5-FC gene
therapy. On the other hand, after the Ad/EFp-BCD/5-FC treatment,
we observed significant weight loss and severe diarrhea, despite
the local administration (Figure 5A). These results strengthen
further the argument that tumour hypoxia is a specific therapeutic
target and our 5HRE system has the advantage of specifically
targeting it.
To determine whether the specific targeting of tumour hypoxia
by the gene therapy strategy improves the efficacy of radiotherapy
in a tumour xenograft, we performed growth delay assays. The
gene therapy synergistically kept tumour growth suppressed in
combination with the single (12.5Gy) and the fractionated
(3Gy 5 fractions) radiotherapy. These results were consistent
with the report that a combination of HRE-driven P450R
expression and tirapazamine significantly increased the efficacy
of radiotherapy in vivo (Cowen et al, 2004). The data together with
ours definitely support that hypoxia-targeting gene therapy
combined with radiotherapy is a promising approach to cancer
treatment.
Although BCD expression from the 5HREp-BCD gene was not
observed under normoxic conditions in the present Western
blotting (Figures 1B and 2B), the cells showed slight but clear
sensitivity to a high concentration of 5-FC even under normoxic
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Figure 5 Synergistic antitumour effect of a combination of gene therapy with IR treatment. (A) Ad/EFp-BCD or Ad/5HREp-BCD was intratumorally
injected into tumor-bearing mice on day 0 (blue arrow head), and 5-FC was administered daily from day 1 to day 5 (red arrow head). Body weight of the
tumour-bearing mice was measured during and after the treatment. The results are the mean of six independent mice7s.d. *Po0.05. **Po0.01. (B and C)
Tumour-bearing mice in the Ad & 5-FC group and Ad & 5-FC & IR group were administered Ad/5HREp-BCD. Those in the Ad & 5-FC group, IR & 5-FC
group, and Ad & 5-FC & IR group were administered 5-FC. The tumour xenografts in the IR group, IR & 5-FC group, and Ad & 5-FC & IR group were locally
exposed to irradiation with a single dose of 12.5Gy (B) or daily dose of 3Gy for 5 days (C). (See Materials and methods for details.) Tumour volume was
measured with calipers and calculated as 0.5 LW
2. Relative tumour volume indicates the ratio of the tumour volume on each day to the corresponding
volume on day 0. The results are the mean of six independent tumours7s.d.
Table 1 Statistical analysis of TGDT
Single (12.5Gy) Fractionated (3Gy 5)
Sham-treatment 8.273.1 9.875.8
Ad & 5-FC 13.275.6 (P¼0.144 vs Sham) 13.074.4 (P¼0.148 vs Sham)
IR 19.474.8 17.073.7
IR & 5-FC 19.873.4 (P¼0.865 vs IR) 16.872.5 (P¼0.644 vs IR)
Ad & 5-FC
&I R
47.2716.8 (Po0.01 vs IR) 43.3723.8 (Po0.05 vs IR)
Abbreviations: 5-FC¼5-fluorocytosine; TGDT¼tumour growth doubling time.
TGDT was calculated as the mean of the days, on which relative tumor volume of
each tumor reached 2-fold of that on day 0. Data were based on the results of the
growth delay assays in Figures 5B and C with single (12.5Gy) and fractionated
(3Gy 5) irradiation, respectively. Results are the mean of the days7s.d. (n¼6).
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sconditions (Figure 3). This sensitivity was observed regardless of
infection with the adenovirus in vitro (Figure 3; compare
MOI¼0–100 in each cell), indicating that an excess dose of
5-FC itself results in BCD-independent cytotoxicity. In our growth
delay assays, a significant difference was not observed in TGDT
between the IR group and the IR & 5-FC group (without
adenovirus administration) (Figure 5B and C and Table 1),
indicating that the dose of 5-FC was not excessive, or rather was
moderate in our in vivo studies. In such an experimental setting,
tumour growth in the Ad & 5-FC & IR group was significantly
delayed compared to that in the IR group (Figure 5B and C and
Table 1). All of these results strongly suggest that the synergistic
therapeutic effect of Ad & 5-FC & IR treatment was dependent on
the expression of BCD and was caused by the conversion of 5-FC to
cytotoxic 5-FU.
Hypoxia-inducible factor-1 plays important roles in regulating
tumour radiosensitivity, and therefore, it has been recognised
as a potentially promising target for tumour radiosensitisation
(Moeller et al, 2004; Moeller and Dewhirst, 2006). Because
transcription from 5HREp mainly depends on HIF-1 activity,
BCD expression from Ad/5HREp-BCD should be induced in the
cells with increased HIF-1 activity. In this regard, the gene therapy
should have targeted the tumour cells with increased HIF-1 activity
and enhanced the therapeutic effect of radiotherapy.
We previously used 5HREp to image hypoxic cells in tumour
xenografts (Harada et al, 2005; Liu et al, 2005). These studies were
conducted using tumour xenografts, in which a hypoxia-respon-
sive gene, such as the 5HREp-luciferase or the 5HREp–GFP gene,
had been previously set, but never using vectors responsible for
the trans-gene delivery. In the present immunohistochemical
analysis, we confirmed the intratumoral expression of BCD after
the direct administration of the adenoviral vector into tumour
xenografts. The expression was limited to and near the pimoni-
dazole-positive hypoxic regions. Moreover, the BCD was biologi-
cally active and indeed led to the antitumour effect we desired.
These results represent great progress toward the clinical use of
this hypoxia-targeting strategy. However, the most important
problem still remains; after the systemic intravenous administra-
tion of Ad/5HREp-BCD, we did not detect the expression of BCD
in the tumour xenografts in the immunohistochemical analysis
(data not shown). For the clinical application of the present gene
therapy strategy, the development of a novel gene delivery
technology is the next issue to be addressed, although work on
this has met with minimal success.
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